High‐dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years

Abstract

The modified HiDAC regimen was well tolerated in patients aged >60 years with AML and was associated with low induction mortality and high rates of CR. Nevertheless, these high remissions still were associated with poor overall outcomes.